Tavotek Biotherapeutics focused on discovering, acquiring, developing, and commercializing therapeutic medicines.
Tavotek Biotherapeutics has raised $35.0M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Tavotek Biotherapeutics's investors include Apricot Capital, BioVenture, GF Xinde Investment Management, Oriza Holdings, New Alliance Capital.
Tavotek Biotherapeutics is headquartered in Gwynedd, United States.
Tavotek Biotherapeutics focused on discovering, acquiring, developing, and commercializing therapeutic medicines.
Tavotek Biotherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tavotek Biotherapeutics — Funding & Investors." VCBacked, November 18, 2021, https://www.vcbacked.co/company/tavotek-biotherapeutics. Accessed October 3, 2026.
VCBacked. (2021). Tavotek Biotherapeutics — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/tavotek-biotherapeutics
{{cite web |title=Tavotek Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tavotek-biotherapeutics |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated